Plasma tumour and metabolism related biomarkers differentiate PAH from HFpEF-PH may improve long-term prognosis. Zheng H, Liang J, Chen X, Chen X, et al. Int J Cardiol 2022;347:64-65.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zheng H, Liang J, Chen X, Chen X, et al. Plasma tumour and metabolism related biomarkers differentiate PAH from HFpEF-PH may improve long-term prognosis. Int J Cardiol 2022;347:64-65.
PMID: 34785242